# A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

> **NCT01714713** · PHASE3 · COMPLETED · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 830 (actual)

## Conditions studied

- Schizophrenia
- Impaired Cognition

## Interventions

- **DRUG:** EVP-6124

## Key facts

- **NCT ID:** NCT01714713
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 830 (ACTUAL)
- **Last updated:** 2016-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01714713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01714713, "A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01714713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*